Clinical Trials Browser

NCT06529822 2026-01-13

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1 Recruiting

32 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05010200 2026-01-07

PGV-Prostate

Phase 1 Active not recruiting

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT04116320 2025-07-14

AM-003

Phase 1 Terminated

5 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT03835533 2024-04-12

PORTER

Phase 1 Completed

43 enrolled 19 charts

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03359239 2023-05-16

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Phase 1 Completed

10 enrolled

Genitourinary

Urologic Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03262103 2022-09-10

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Phase 1 Completed

13 enrolled

Genitourinary

Prostatic Neoplasms

NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Phase 1 Completed

34 enrolled

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

NCT00694551 2019-10-04

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Phase NA Completed

29 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Phase 1/2 Completed

70 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell